Nykode’s APC targeted vaccine technology can be delivered as mRNA and generate strong T cell responsesNykode’s APC targeted vaccine technology consistently results in faster, broader and stronger immune response compared to non-targeted vaccines, whether delivered as DNA or mRNA OSLO, Norway, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced it is p